Geriatric patients with CKD are at high risk for morbidity and mortality from the potential side effects of treatments.
Elevated levels of Hcy are associated with increased levels of cardiovascular inflammation.
A new systematic literature review has found that it may not be cost-effective to provide primary screening for CKD in the general population.
Lower risk with no increase in bleeding regardless of CKD severity.
Ferumoxytol and iron sucrose have comparable safety in the treatment of anemia in patients with CKD.
Full lipid profiles are recommended for all patients with chronic kidney disease at first presentation.
The risk if nearly 10 times greater among hemodialysis patients than individuals without CKD.
Frequent events included high venous hemoglobin and hyperkalemia.
Higher quartiles of net endogenous acid production in elderly CKD patients were associated with an increased risk of a 25% decline in estimated glomerular filtration rate.
The Canadian Society of Nephrology recommends initiation when clinical indications emerge or when the eGFR 6 mL/min/1.73 m2 or below.
These include diastolic dysfunction, a history of MI, age older than 75 years, and elevated troponin T.
The presence of cardiovascular disease in RA patients increases their risk of impaired renal function.
In a study, ferumoxytol and iron sucrose treatment was associated with comparable increases in hemoglobin levels and adverse event rates.
Parietal cells cause scarring in the absence of podocytes.
Other predictors included a history of myocardial infarction, elevated troponin T, and age older than 75.
A repeat measurement has no added prognostic value in CKD patients, study finds.
Patients with end-stage renal disease at admission into a surgical ICU also are at increased risk of organ failure, study finds.
ACE inhibitors and angiotensin-receptor blockers lower the risk for long-term dialysis, death with advanced kidney disease.